论文部分内容阅读
目的探讨解聚复肾宁(JJFSN)对DN患者血清CTGF和MMP-9的影响。方法研究对象为某院收治的120例早期2型DN患者,将其随机分为解聚复肾宁组、厄贝沙坦组、解聚复肾宁+厄贝沙坦组、对照组。每组各30例,12周为1疗程,观察各组治疗前后相关指标的变化。结果解聚复肾宁组治疗后空腹血糖、24 h尿微量白蛋白排泄率、血肌酐、糖化血红蛋白等指标显著好转,血清CTGF显著降低,MMP-9显著升高(P0.05)。结论解聚复肾宁可能是通过改善血清CTGF、MMP-9水平而影响细胞外基质代谢调控系统,延缓DN的进展。
Objective To investigate the effect of JJFSN on serum CTGF and MMP-9 in DN patients. Methods A total of 120 early type 2 DN patients admitted to a hospital were randomly divided into depolymerizing Fu Shen Ning group, irbesartan group, depolymerizing Fu Shen Ning + irbesartan group and control group. Each group of 30 cases, 12 weeks for a course of treatment, observed changes in the relevant indicators before and after treatment in each group. Results After fasting blood glucose, 24 h urine microalbumin excretion rate, serum creatinine, HbA1c and other indexes were significantly improved after deprivation Shufundinning treatment, serum CTGF was significantly decreased, and MMP-9 was significantly increased (P <0.05). Conclusion Disintegrating Fu Shen Ning may affect the extracellular matrix metabolism regulatory system and delay the progression of DN by improving serum levels of CTGF and MMP-9.